GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China Isotope & Radiation 1763.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

11.49

-1.96%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥7.00bn

FY2016FY2025

Net income

CN¥319.0m

FY2016FY2025

Free cash flow

−CN¥13.8m

FY2016FY2025

Shareholders' equity

CN¥5.23bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥7.00bnCN¥7.57bnCN¥6.63bnCN¥6.15bnCN¥5.14bnCN¥4.27bnCN¥3.99bnCN¥3.24bnCN¥2.67bnCN¥2.36bn
Gross profitCN¥3.52bnCN¥3.68bnCN¥3.48bnCN¥3.51bnCN¥3.24bnCN¥2.62bnCN¥2.83bnCN¥2.29bnCN¥1.88bnCN¥1.66bn
Research and developmentCN¥294.1mCN¥300.3mCN¥306.1mCN¥300.5mCN¥196.2mCN¥152.5mCN¥102.7mCN¥73.0mCN¥73.5mCN¥58.7m
Operating incomeCN¥916.2mCN¥1.09bnCN¥941.6mCN¥914.0mCN¥742.9mCN¥614.8mCN¥670.0mCN¥676.7mCN¥530.1mCN¥504.4m
Net incomeCN¥319.0mCN¥406.6mCN¥371.0mCN¥392.3mCN¥335.8mCN¥213.6mCN¥329.0mCN¥323.0mCN¥271.5mCN¥262.1m
Diluted earnings per share1.001.271.161.231.050.671.031.011.130.82

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥15.72bnCN¥14.77bnCN¥13.19bnCN¥11.69bnCN¥10.47bnCN¥9.19bnCN¥8.84bnCN¥6.86bnCN¥4.70bnCN¥3.58bn
Cash and short-term investmentsCN¥2.59bnCN¥2.63bnCN¥2.94bnCN¥2.93bnCN¥2.79bnCN¥2.56bnCN¥2.79bnCN¥2.59bnCN¥1.48bnCN¥1.00bn
Total liabilitiesCN¥7.59bnCN¥7.02bnCN¥6.05bnCN¥5.13bnCN¥4.44bnCN¥3.68bnCN¥3.84bnCN¥2.56bnCN¥2.25bnCN¥2.11bn
DebtCN¥2.73bnCN¥2.57bnCN¥1.70bnCN¥903.9mCN¥856.6mCN¥719.7mCN¥873.6mCN¥150.0mCN¥150.0mCN¥480.0m
Shareholders' equityCN¥5.23bnCN¥5.01bnCN¥4.69bnCN¥4.47bnCN¥4.18bnCN¥3.89bnCN¥3.76bnCN¥3.47bnCN¥1.87bnCN¥927.5m
Shares outstanding320m320m320m320m320m320m320m318m240m320m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥538.3mCN¥142.5mCN¥85.0mCN¥862.7mCN¥794.3mCN¥291.9mCN¥601.9mCN¥577.7mCN¥429.8mCN¥457.6m
Capital spending−CN¥552.1m−CN¥1.03bn−CN¥897.6m−CN¥534.0m−CN¥427.7m−CN¥409.9m−CN¥590.7m−CN¥751.0m−CN¥245.6m−CN¥126.0m
Free cash flow−CN¥13.8m−CN¥889.7m−CN¥812.7mCN¥328.7mCN¥366.6m−CN¥118.0mCN¥11.2m−CN¥173.3mCN¥184.2mCN¥331.7m
Dividends paid−CN¥124.7m−CN¥123.3m−CN¥141.0m−CN¥120.9m−CN¥57.7m−CN¥44.4m−CN¥100.2m−CN¥90.5m−CN¥177.5m−CN¥319.0m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥2.99bnCN¥4.14bnCN¥2.86bnCN¥4.76bnCN¥2.81bnCN¥3.89bnCN¥2.74bnCN¥3.53bn
Gross profitCN¥1.47bnCN¥2.06bnCN¥1.46bnCN¥2.22bnCN¥1.46bnCN¥2.00bnCN¥1.48bnCN¥1.98bn
Operating incomeCN¥463.5mCN¥458.6mCN¥457.6mCN¥677.0mCN¥409.4mCN¥600.8mCN¥327.1mCN¥567.2m
Net incomeCN¥159.0mCN¥147.0mCN¥172.0mCN¥252.1mCN¥154.5mCN¥244.1mCN¥126.9mCN¥280.3m
Diluted earnings per share0.500.460.540.790.480.760.400.88
Cash from operationsCN¥64.0mCN¥761.0m−CN¥244.0mCN¥258.0m−CN¥116.0mCN¥376.0m−CN¥291.0mCN¥950.0m
Capital spending−CN¥214.0m−CN¥369.0m−CN¥194.0m−CN¥586.0m−CN¥445.0m−CN¥651.0m−CN¥245.0m−CN¥447.0m
Free cash flow−CN¥150.0mCN¥392.0m−CN¥438.0m−CN¥328.0m−CN¥561.0m−CN¥275.0m−CN¥536.0mCN¥503.0m
Total assetsCN¥16.08bnCN¥15.72bnCN¥15.65bnCN¥14.77bnCN¥13.74bnCN¥13.19bnCN¥11.80bnCN¥11.69bn
Cash and short-term investmentsCN¥2.55bnCN¥2.59bnCN¥2.69bnCN¥2.63bnCN¥3.01bnCN¥2.87bnCN¥2.38bnCN¥2.95bn
DebtCN¥2.90bnCN¥2.73bnCN¥3.02bnCN¥2.57bnCN¥2.05bnCN¥1.70bnCN¥1.02bnCN¥903.9m
Shareholders' equityCN¥5.31bnCN¥5.23bnCN¥5.08bnCN¥5.01bnCN¥4.75bnCN¥4.69bnCN¥4.45bnCN¥4.47bn

Financial ratios

Data as of 13 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin50.3%48.6%52.5%57.2%63.0%61.2%
Operating margin13.1%14.0%14.4%14.2%14.4%13.6%
Net margin4.6%5.4%5.6%6.4%6.5%5.0%
Return on equity6.1%8.1%7.9%8.8%8.0%5.5%
Return on assets2.0%2.8%2.8%3.4%3.2%2.3%
Free cash flow yield27.8%30.0%25.1%35.6%31.2%17.9%
Revenue growth-7.6%14.2%8.0%19.5%20.3%7.2%
Earnings growth-21.6%9.6%-5.4%16.8%57.2%-35.1%
Current ratio1.76x1.78x1.93x1.88x1.68x2.08x
Debt to equity0.51x0.50x0.35x0.19x0.20x0.17x
Equity ratio33.3%33.9%35.6%38.2%39.9%42.4%
Interest coverage13.24x21.91x26.52x24.76x20.75x16.60x
R&D as a share of sales4.2%4.0%4.6%4.9%3.8%3.6%
Buybacks as a share of market value0.0%0.0%0.0%0.0%0.0%-0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.4%10.4%12.5%
Operating income0.1%8.3%7.1%
Net income-6.7%8.4%2.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin49.4%51.9%54.5%59.0%
Operating margin13.7%14.1%14.2%15.7%
Net margin5.0%5.4%5.5%6.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings17.87.510.19.618.435.418.013.4
Price to sales0.80.40.60.61.21.81.51.3

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 23 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.260.5060.7370.4790.440.2170.1520.139

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.